Collaboration is essential to accelerate research.
The Amyloidosis Research Consortium has an end-to-end research model focused on accelerating the development of and access to new, effective treatments. Our major research initiatives and programs are designed to navigate and eradicate the hurdles standing in the way of progress, attract more investment and expand the amount of data available to drive progress.
Fostering and supporting collaborative projects to optimize research from the laboratory bench to the patients’ bedside.
Working with our industry and academic partners to prioritize, define and deliver a portfolio of clinical trials, real-world evidence and natural history studies that aim to answer important clinical research questions and evolve new treatments.
Promoting and enabling data sharing within the community to advance research efforts and understanding of the disease.
Conducting a pioneering, patient-preference elicitation study which highlights the perspectives that patients and caregivers have regarding the potential benefits and risks of various treatment options into the spotlight.
In early 2018, ARC held a research roundtable that brought together the amyloidosis community to develop a stakeholder-wide blueprint, thereby aligning research priorities most likely to make a significant, material contribution to improving patient outcomes. This blueprint will directly shape ARC’s research strategy and ensure our future investments will have the greatest impact on patients. The research paper will be published in July.
ARC will also support other research efforts in several ways. We are particularly interested in stimulating and advancing the careers of young researchers and physicians working in the field.